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Summary
The dramatic recent rise in the incidence of allergic or autoimmune inflam-
matory diseases in the West has been proposed to reflect the lack of appro-
priate priming of the immune response by infectious agents such as parasitic
worms during childhood. Consistent with this, there is increasing evidence
supporting an inverse relationship between worm infection and T helper type
1/17 (Th1/17)-based inflammatory disorders such as rheumatoid arthritis,
inflammatory bowel disease, type 1 diabetes and multiple sclerosis. Perhaps
more surprisingly, given that such worms often induce strong Th2-type
immune responses, there also appears to be an inverse correlation between
parasite load and atopy. These findings therefore suggest that the co-evolution
of helminths with hosts, which has resulted in the ability of worms to modu-
late inflammatory responses to promote parasite survival, has also produced
the benefit of protecting the host from pathological lesions arising from
aggressive proinflammatory responses to infection or, indeed, aberrant
inflammatory responses underlying autoimmune and allergic disorders. By
focusing upon the properties of the filarial nematode-derived immunomodu-
latory molecule, ES-62, in this review we shall discuss the potential of exploit-
ing the immunomodulatory products of parasitic worms to identify and
develop novel therapeutics for inflammation.
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Introduction
Filarial nematodes are parasitic worms that may protect
from autoimmune and allergic inflammation. Although
these worms are capable of inducing particularly severe
pathology, including debilitating skin lesions, elephantiasis
and blindness, the majority of infected individuals appear to
be relatively asymptomatic, even when harbouring consid-
erable parasite burdens [1,2]. Infection with such filarial
nematodes is long term, with individual worms surviving for
up to 10 years [2], and this has been proposed to be due to
their ability to modulate and hence evade the host immune
system. Indeed, analysis of those infected individuals free of
pathology reveals an immunological phenotype that tends to
be T helper type 2 (Th2)-polarized, anti-inflammatory and
associated with regulatory components [3,4]. Similar Th2/
regulatory strategies also appear to be utilized by gastrointes-
tinal (GI) nematodes [5], indicating that these immune
evasion mechanisms are a general feature of nematode infec-
tion which, in addition to promoting parasite survival, are
conducive to host health by limiting development of patho-
logical lesions resulting from aggressive, proinflammatory
responses. This would provide a considerable advantage for
humans, as although nematode infection can result in severe
pathology the majority of infected people exhibit little
evidence of an inflammatory response or overt tissue
destruction/disruption [6].
Interestingly, such immunomodulation has also, in some
cases, been reported to extend to the subsequent Th1/Th17-
dependent responses of the infected individual to vaccines
[7], suggesting that nematode-driven changes in immune-
responsiveness could impact upon susceptibility to infection
with other pathogens. Arising from this, there is currently
great interest in the idea that the recent alarming increase in
Th1/Th17-associated inflammatory autoimmune diseases
in the industrialized but not developing world reflects
increased hygiene, causing a reduction in infection with
pathogens such as these parasitic worms (the ‘hygiene
hypothesis’) [8]. Indeed, while it has long been suspected
that autoimmune diseases may be less prevalent in areas
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endemic for nematodes [9], there is now increasing epide-
miological evidence for an inverse relationship between
nematode infection and inflammatory disorders such as
inflammatory bowel disease, type 1 diabetes, rheumatoid
arthritis, multiple sclerosis and autoimmune liver disease
[9–13]. Moreover, these human studies have been comple-
mented recently by direct experimental evidence of the pro-
tection afforded by parasitic nematodes in animal models of
inflammatory autoimmune diseases such as colitis and dia-
betes [14–17].
Intriguingly, given the Th2-associated phenotype of
nematode infection [18], although there are cases in which
no association or, indeed, increased susceptibility have been
observed, the majority of studies suggest that nematode
infection can also protect against allergic inflammation
[7–9,18–20]. In human epidemiological studies such protec-
tion is evidenced by factors such as skin reactivity to aller-
gens or wheezing and by comparing symptoms before and
after anthelmintic treatment [7,9,19–21]. Again, these find-
ings have been reinforced by direct experimental evidence
showing protective effects of nematode infection in animal
models of peanut and house dust mite (Der p1) allergy as
well as asthma [22–26]. While the Th2 phenotype resulting
from nematode infection could clearly provide a mechanism
to explain the ability of the helminths to inhibit Th1/Th17-
associated inflammation, it obviously cannot explain how
nematodes suppress allergic diseases, which themselves are
Th2-dependent [18]. However, both Th1 and Th2 responses
may be restricted by regulatory responses [27], and perhaps
consistent with this it has been proposed that the ability of
nematodes such as Heligmosomoides polygyrus [25] to inhibit
allergic airway inflammation and Litomosoides sigmodontis
to inhibit airway hyper-reactivity but not lung inflammation
[28] may be due to the generation of regulatory T cells (Tregs).
Collectively, therefore, the idea that the immune evasion
strategies developed to promote survival by such helminths
can also protect against human allergic and autoimmune
inflammatory disease has, not surprisingly, led to the
consideration of the therapeutic potential of parasitic
nematodes. Thus, within the past few years, certain species of
these worms have been employed in clinical trials for the
treatment of inflammatory diseases such as Crohn’s disease
[9,10,29] and asthma [20].
Although these clinical trials have met with some success
due to the ethical problems and risks inherent in using
potential pathogens as therapeutics, much interest has
focused recently upon the identification of the parasite-
derived molecules responsible for the immunomodulation
in order to employ them (or small molecule derivatives) for
the safe treatment of human disease. Some progress relating
to a number of parasite-derived immunomodulators from
several nematodes has been made recently on this front
[30–36]. However, the most well-defined nematode-derived
immunomodulatory molecule to date is ES-62, a phos-
phorylcholine (PC)-containing glycoprotein secreted by the
rodent filarial nematode Acanthocheilonema viteae and
found subsequently to have well-conserved orthologues in
human filarial nematode parasites, including Brugia malayi
and Onchocerca volvulus [31,32,37,38]. ES-62 exhibits a wide
range of anti-inflammatory properties [37,39,40] and as a
consequence of this, the molecule has been tested in mouse
models of both autoimmune and allergic disease and has
been found to be active against collagen-induced arthritis
[41] and type I hypersensitivity in the skin and lungs [42].
For the rest of this review we shall focus, therefore, upon the
anti-inflammatory actions of ES-62 and how we can exploit
ES-62 to identify potential therapeutic targets for human
inflammatory diseases.
ES-62 and its mechanism of action
ES-62 is a tetrameric glycoprotein (62 kDa subunits) that has
PC-moieties attached via an N-type glycan and has highest
sequence homology (37–38% identity) with members of the
M28 peptidase family [38]. Although a function for the puta-
tive peptidase activity of ES-62 has not yet been demonstrated
convincingly, many of its immunomodulatory effects have
been attributed to the presence of PC [39,40]. These immu-
nomodulatory actions include modulation of B cell prolifera-
tion and cytokine production, polarization of the responses
of antigen presenting cells (APCs) such as dendritic cells
(DCs) and macrophages towards an anti-inflammatory,
hyporesponsive phenotype and desensitization of mast cell
degranulation [31,32,39,40]. That the activity of ES-62 is
dependent largely upon its PC-moiety has been demon-
strated by studies in which normal and PC-free ES-62 were
compared [43] and in which ES-62 was compared with
PC-conjugated to proteins such as bovine serum albumin
(BSA) or ovalbumin (OVA) [44,45]. These studies not only
confirmed that PC-conjugates could indeed mimic ES-62-
mediated modulation of B cell function and APC maturation
in vitro, but could also induce much of the humoral and T cell
effector polarization observed in response to ES-62 to in vivo.
PC is a pathogen-associated molecular pattern (PAMP)
expressed by a diverse range of organisms, including bacte-
ria, fungi and protozoa, as well as filarial and gastrointestinal
nematodes [46]. Although it enables detection of pathogens
by the host (for example via antibodies or C-reactive
protein), it can also function to promote pathogen survival
via modulation of the host immune response. Consistent,
therefore, with the suggestion that the PC-PAMP is respon-
sible for many of the observed immunomodulatory effects,
ES-62 activity is dependent upon the presence of Toll-like
receptor (TLR)-4 on the target cell. This was demonstrated
by the finding that macrophages and DCs from TLR-4 (but
not TLR-2 or TLR-6) knock-out (KO) mice were found to be
unresponsive to ES-62 [47], and also by studies showing that
the modulatory effects of ES-62 on mast cells were abrogated
following knock-down of TLR-4 levels by the use of an
anti-sense oligonucleotide approach [42]. However, ES-62
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appears to signal via TLR-4 in a non-classical manner as,
unlike lipopolysaccharide (LPS), ES-62 is fully active against
APC derived from HeJ mice that have a mutation in the
Toll-interleukin-1 receptor (TIR) domain of TLR-4 [45,47].
A key feature of such ES-62 action in target cells appears to
be its ability to induce down-regulation of the signalling
enzyme, protein kinase C (PKC)-a. This was first shown in B
lymphocytes [48,49], where PKC-a is important for prolif-
eration, and hence such down-regulation contributed to the
observed ES-62-mediated inhibition of B cell proliferation.
Subsequently it was found that ES-62 caused a similar deg-
radation of PKC-a in mast cells; thus, complexing of ES-62
and TLR4 at the plasma membrane results in sequestration
of PKC-a followed by caveolae/lipid raft-dependent inter-
nalization and non-proteosomal degradation at the peri-
nuclear region of the cell [42]. As PKC-a is necessary for
the phosphatidylcholine-specific phospholipase D (PLD)-
coupled, sphingosine kinase-mediated, calcium mobilization
that is required for mast cell degranulation, such down-
regulation of PKC-a provides the molecular mechanism
underpinning ES-62-mediated desensitization of FceRI-
coupled mast cell responses [42]. By contrast, sequestration
and degradation of PKC-a does not occur when ES-62 is
substituted by LPS, and indeed such LPS/TLR-4 signalling
enhances FceRI-mediated mast cell responses, findings again
highlighting the non-canonical nature of ES-62/TLR-4 sig-
nalling by which ES-62 subverts the host immune response.
Therapeutic potential of ES-62
Rheumatoid arthritis (RA) has long been associated with an
aberrant Th1 immunological phenotype, in which excess
proinflammatory cytokine production within the inflamed
RA synovial membrane contributes directly to cartilage/
bone erosion through matrix metalloproteinase production
and dysregulated chondrocyte/osteoclast function [50,51].
However, recent identification of the interleukin (IL)-17
inflammatory axis has led to a reassessment of the patho-
physiology of RA as being representative of IL-17/
Th17- rather than Th1-dependent inflammation [50,51].
Nevertheless, in the pre-IL-17 era, as we had previously
found ES-62 to dampen aggressive Th1-associated proin-
flammatory responses [52], we investigated the prophylactic
effect of ES-62 on the development of collagen-induced
arthritis (CIA) in mice [41]. ES-62 suppressed the severity of
developing CIA significantly and, as predicted, these prophy-
lactic effects correlated with the inhibition of collagen-
specific proinflammatory/Th1 cytokine production [tumour
necrosis factor (TNF)-a, IL-6 and interferon (IFN)-g] and
suppression of collagen-specific immunoglobulin (Ig)G2a
antibodies but without inducing a corresponding increase in
Th2-associated responses. Importantly, therapeutic admin-
istration of ES-62 after onset of established joint pathology
also resulted in significant reduction in arthritis progression
both in terms of the number of subsequently recruited
arthritic joints and also progression of articular inflamma-
tion and destruction [41,44]. Notably, many of these protec-
tive effects could be mimicked by PC-OVA but not by
PC-free rES-62 [44]. To investigate further the therapeutic
potential of ES-62 in humans, we performed parallel studies
on primary cultures from RA synovial fluid and membranes
that showed significant suppression of LPS-induced TNF-a
and IL-6 in the presence of ES-62. Moreover, peripheral
blood mononuclear cells (PBMCs) and synovial fluid and
membrane cultures from patients with RA, stimulated with
the cytokines IL-12, IL-15 and IL-18 to mimic the proinflam-
matory milieu of the joint [50], were found to exhibit
reduced capacity to secrete the signature Th1 cytokine,
IFN-g, when pre-exposed to ES-62 or OVA-PC but not
rES-62 or OVA [44]. Collectively, these findings indicated
clearly that ES-62 could modify critical arthritogenic proin-
flammatory pathways in disease-relevant tissues [50].
With respect to allergic inflammation, ES-62 was found
to be protective in mouse models of OVA-induced airway
hypersensitivity and immediate-type hypersensitivity (ITH)
to oxazolone in the skin [42]. In the airway hypersensitivity
model, ES-62 was found to reduce peribronchial inflamma-
tion and mucosal hyperplasia, inhibit eosinophila and
prevent release of IL-4, the signature cytokine required for
development of airway inflammation. In the skin ITH
model, ES-62-mediated reduction of ear swelling correlated
with ES-62 directly suppressing FceRI-mediated mast cell
degranulation and inflammatory mediator release.
ES-62 has now therefore been demonstrated to exhibit
anti-inflammatory potential in both Th1- and Th2-
polarized models of inflammatory disease: the precise
mechanisms involved have not been defined, but unlike the
situation with suppression of airway hyper-reactivity by
infection with H. polygyrus [25] and L. sigmodontis [28],
ES-62 does not appear to act via the induction of Tregs [53].
Moreover, ES-62 does not appear to be merely immunosup-
pressive, as it has failed to modulate the Th1 responses
associated with the Bacillus Calmette–Guérin (BCG) vaccine
component purified protein derivative (PPD) [54], as well as
those associated with other filarial nematode antigens
such as Onchocerca volvulus-fatty acid and retinol-binding-1
(rOv-FAR-1) and recombinant Onchocerca volvulus-
activation associated secreted protein-1 (Ov-ASP-1) [55].
Similarly, ES-62 did not suppress the Th1-like pathology
associated with Toxoplasma gondii [56] and Plasmodium cha-
baudi [57], nor did it modulate the responses to Leishmania
major in either susceptible or resistant strains of mice (Xu,
Harnett & Harnett; unpublished results). Collectively, these
results suggest that ES-62 may be effective against a particu-
lar type of inflammation, which in the light of the recent
reassessment of CIA/RA as being representative of IL-17/
Th17- rather than Th1-dependent inflammation [50,58]
might suggest that ES-62 can only target Th-1 (rheumatoid
arthritis)- and Th-2 (allergy/asthma)-type inflammatory
disorders that are IL-17-dependent [50,58,59]. Importantly,
M. M. Harnett et al.
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however, they also indicate that while ES-62 can dampen
the pathological responses associated with inflammatory
autoimmune and allergic disorders, unlike current biologics
such as TNF blockers, it is unlikely to compromise the host
in terms of vaccine responses or mounting responses to
other pathogens [54–57].
Future perspectives
The finding that ES-62 can suppress the pathology associated
with autoimmune and allergic inflammatory disorders
without compromising the host’s ability to fight disease sug-
gests that therapies based on the mode of action of ES-62
may provide the starting point in the development of safe
effective drugs for treatment of such human diseases. Thus,
to address identifying a ‘blueprint’ of the anti-inflammatory
action of ES-62, we conducted gene microarray studies on
synovial membrane cultures from rheumatoid arthritis
patients. Analysis of the genes modulated by LPS and ES-62
in synovial membrane cultures from rheumatoid arthritis,
but not osteoarthritis, patients (Table 1 and unpublished
results) showed that many classes of immunoregulatory
genes, including chemokines, cytokines, inflammatory
mediators and their receptors, were targeted differentially.
Similarly, genes involved in antigen processing and traffick-
ing as well as intracellular signalling elements such as kinases
and phosphatases, components of the ubiquitin pathways
such as E3 ligases, de-ubiquitin enzymes (DUBs) and pro-
teosomal subunits as well as transcription factors which are
likely to be involved in directing the phenotype of the
immune response were regulated differentially. Moreover, in
some cases, co-culture with ES-62 could reverse the LPS
phenotype. Thus, while many of the observed changes were
small, LPS, for example, up-regulated expression of pro-
inflammatory mediators (e.g. CXCL6, CCL11, HMGB1),
pattern recognition receptors (e.g. TLR-4 and various scav-
enger receptors), co-stimulatory and adhesion molecules
[e.g. CD80, lymphocyte function-associated antigen 1
(LFA-1) and LFA-3] as well as folistatin, a novel auto-
antigen/biomarker that has been shown recently to play a
critical role in arthritis [61]. By contrast, ES-62 promoted the
up-regulation of negative immunoregulatory receptors such
as the immunoreceptor tyrosine-based inhibition motifs
(ITIM)-containing LILRB members of the leucocyte
immunoglobulin-like receptor family. Interestingly, both
membrane and soluble forms of LILRB2 have been shown to
exhibit potent immunosuppressive activity, and therefore
have been proposed as exploitable in the treatment of trans-
plant rejection, cancer, asthma and autoimmunity [62–64].
With relevance to arthritis, for example, LILRB2 receptors
have been implicated in the suppression of osteoclasts
responsible for bone resorption and hence articular erosion
[63]. Interestingly, polymorphisms in the LILRB class of
receptors have been associated with human leucocyte
antigen (HLA)-DRB1 shared epitope-negative rheumatoid
arthritis and, indeed, LILRB1 is encoded within the leuco-
cyte receptor complex on chromosome19q13.4, implicated
previously as a susceptibility region for systemic lupus
erythematosus [65]. Closer analysis revealed that while many
genes were up-regulated by both LPS and ES-62 (Table 2), a
number such as complement receptor of the immunoglobu-
lin family (CRIg), macrophage receptor with collagenous
structure (MARCO), LILRB2, neuromedin U, fucosyltrans-
ferase 4 (FUT4) and cytochrome P450 2J2 (CYP2J2) were
quite differentially regulated by these TLR-4 ligands, being
very strongly up-regulated by ES-62 but not LPS. Interest-
ingly, reduced CRIg [67,68] and MARCO [69–71] signalling
has been implicated in the development of autoimmune
inflammatory disorders while FUT4 [85,92] and neurome-
din [81–84] appear to act to polarize towards Th2 responses
and CYP2J2 [86,87] acts to produce anti-inflammatory
arachidonic acid metabolites. While this type of analysis
indicates that the mechanisms underlying ES-62-mediated
suppression of inflammatory pathology are complex and
manifold, the challenge is to assess experimentally and
dissect the relative contribution of such signals to the anti-
inflammatory action of ES-62 in vivo. Neverthless, this
approach indicates that such studies involving a range of
parasite-derived immunomodulators that exploit distinct
immunoregulatory mechanisms are likely to be of value
in the development of ‘blueprints’ predictive of anti-
inflammatory pathways in clinically relevant tissues that may
identify safe, novel therapeutic targets.
The great challenge, however, is to develop small molecule
derivatives (SMDs) or peptide mimetics of ES-62 (and other
nematode-derived immunomodulatory molecules) for use
as anti-inflammatory drugs to target such pathways. One
possible avenue of exploration is provided by our findings
that the PAMP-PC moiety appears to be responsible for
many of the immunomodulatory and therapeutic effects of
ES-62 [38,40,44,45]. Thus, as we have also shown that gly-
cosphingolipids of Ascaris suum have PC immunomodula-
tory moieties [93], as a first step in generating SMDs
we tested the anti-inflammatory potential of synthetic
PC-containing glycolipids in in vitro assays of macrophage
and DC cytokine production which indicated that although
PC is an immunomodulatory component, other structural
features are necessary to allow it to act [94]. We found a
similar picture in preliminary studies with PC-containing
peptides and this led us to develop a range of compounds
based upon these structures which have shown promise both
in in vitro assays of cytokine and autoantibody production
from blood and PBMC cultures from rheumatoid arthritis
patients, and also prophylactically and therapeutically in the
CIA model (GB Patent 0707724·1 and unpublished results).
Collectively, these data suggest that synthetic PC-based mol-
ecules have the potential to be successful anti-inflammatory
drugs.
A potential second approach builds on the ability of ES-62
to modulate signal transduction pathways selectively in
Anti-inflammatory potential of ES-62
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Table 1. Differential regulation of genes in synovial membranes cultured with lipopolysaccharide (LPS) or ES-62 from rheumatoid arthritis patients.
LPS ES-62 ES-62/LPS Name Description
1·75 -1·11 1·49 CXCL6 Chemokine ligand 6 (granulocyte chemotactic protein 2)
3·46 CCL11 Chemokine ligand 11 (eotaxin)
-1·04 1·27 1·11 CSF2RB Colony stimulating factor 2 receptor, beta chain
-2·30 -1·88 LIFR Leukaemia inhibitory factor receptor
2·50 -1·37 2·39 IL-2RG Interleukin-2 receptor, gamma chain
1·25 -2·44 -1·54 IL-8 Interleukin-8
2·13 -1·66 1·29 IL-8 Interleukin-8 C-terminal variant (IL-8)
2·00 IL-11RA Interleukin-11 receptor, alpha chain
-2·45 IL-13RA2 Interleukin-13 receptor, alpha 2 chain
-1·77 2·11 TGF-BR3 Transforming growth factor, beta receptor III
3·03 4·35 TNF-SF15 Tumour necrosis factor (ligand) superfamily, member 15
-1·85 TNF-RSF11B Tumour necrosis factor receptor superfamily, member 11b
2·68 1·73 TNF-RSF21 Tumour necrosis factor receptor superfamily, member 21
2·30 RIPK1 Receptor (TNFRSF)-interacting serine-threonine kinase 1
1·40 1·35 HMGB1 High-mobility group box 1
-2·13 C1QBP Complement component 1q- binding protein
-1·84 -2·41 MASP2 Mannan-binding lectin serine protease 2
-1·20 2·99 2·06 DEFB1 Defensin, beta 1
-4·50 HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD)
2·38 LILRB1 Leucocyte immunoglobulin-like receptor, subfamily B1 (ITIM)
33·36 23·10 LILRB2 Leucocyte immunoglobulin-like receptor, subfamily B2 (ITIM)
7·57 LILRB3 Leucocyte immunoglobulin-like receptor, subfamily B3 (ITIM)
11·71 12·38 Z39IG Immunoglobulin superfamily protein
1·87 2·25 LAIR1 Leucocyte-associated Ig-like receptor 1
3·41 5·39 IGSF6 Immunoglobulin superfamily, member 6
2·03 1·97 CD80 CD80 antigen (CD28 antigen ligand 1, B7-1 antigen)
1·16 -1·06 1·02 CLECSF2 C-type (calcium dependent, carbohydrate-recognition domain) lectin
-1·48 1·00 -1·10 CLECSF6 C-type (calcium dependent, carbohydrate-recognition domain) lectin
2·57 2·97 COLEC12 Collectin subfamily member 12
2·50 2·19 CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast)
5·28 3·89 LMAN1 Lectin, mannose-binding, 1
3·36 ITGAL Integrin, alpha L (CD11A (p180), LFA-1)
1·84 2·11 CD58 CD58 antigen, (LFA- 3)
2·16 LGALS9 Lectin, galactoside-binding, soluble, 9 (galectin 9)
3·78 -1·64 1·68 MSR1 Macrophage scavenger receptor 1
-1·38 1·65 1·31 MRC2 Mannose receptor, C type 2
1·53 1·36 SCARB2 Scavenger receptor class B, member 2
3·84 TLR-4 Toll-like receptor 4
-1·67 IRAK3 IL-1 receptor-associated kinase 3
-1·24 1·44 1·62 PELI2 Pellino homologue 2 (Drosophila)
2·97 1·93 CASP1 Caspase 1, apoptosis-related cysteine protease (IL-1b, convertase)
1·05 -13·18 -1·09 HSPCA Heat shock 90 kDa protein
2·77 2·27 HSPA8 Heat shock 70 kDa protein 8
3·03 2·19 FSTL1 Follistatin-like 1
-2·31 -1·09 ACVR1 Activin A receptor, type I
1·45 -1·19 1·78 ARIH1 Ariadne homologue, ubiquitin-conjugating enzyme E2 binding protein-1
1·18 -1·00 1·07 FBXW2 F-box and WD-40 domain protein 2
1·11 -2·25 1·83 UBE3A Ubiquitin protein ligase E3A
3·14 -1·53 2·66 RNF13 Ring finger protein 13
-1·31 PSMC3 Proteasome (prosome, macropain) 26S subunit, ATPase, 3
-2·71 -1·04 LRAP Leucocyte-derived arginine aminopeptidase
1·25 -1·04 -1·14 ADAM10 A disintegrin and metalloproteinase domain 10
1·16 -1·08 1·64 LOC64167 Aminopeptidase
4·06 CPVL Carboxypeptidase, vitellogenic-like
M. M. Harnett et al.
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Table 1. Continued
LPS ES-62 ES-62/LPS Name Description
2·50 KEL Kell blood group
2·75 TLL1 Tolloid-like 1
-1·35 1·46 TIMP3 Tissue inhibitor of metalloproteinase 3 (pseudoinflammatory)
-2·81 -4·66 CST6 Cystatin E/M
-2·07 CAPN7 Calpain 7
1·97 1·56 CTSF Cathepsin F
1·51 SERPINB6 Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin) 6
-2·35 SIAT1 Sialyltransferase 1 (beta-galactoside alpha-2,6-sialyltransferase)
1·49 -1·37 1·53 CANX Calnexin
1·45 -1·05 1·41 SNX5 Sorting nexin 5
1·56 -1·01 1·37 FLJ11116 Similar to rab11-binding protein
2·25 -1·66 2·16 GDI2 GDP dissociation inhibitor 2
2·79 2·00 RNP24 Coated vesicle membrane protein
2·13 2·22 NAPA N-ethylmaleimide-sensitive factor attachment protein, alpha
2·25 -1·66 2·16 GDI2 GDP dissociation inhibitor 2
-1·46 1·34 SH3BP5 SH3-domain binding protein 5 (BTK-associated)
1·32 -1·28 1·35 AWP1 Protein associated with PRK1
-1·09 1·29 1·34 PRKRIR Protein-kinase, interferon-inducible dsRNA dependent P58 repressor
-1·19 1·16 -1·01 SNK Serum-inducible kinase
-2·03 MARK3 MAP/microtubule affinity-regulating kinase 3
1·75 1·93 CSNK1A1 Casein kinase 1, alpha 1
1·46 1·48 NCK1 NCK adaptor protein 1
-1·83 2·27 LIM LIM protein (similar to rat protein kinase C-binding enigma)
-1·83 -2·45 DYRK2 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2
-1·92 -1·19 STK17B Serine/threonine kinase 17b (apoptosis-inducing)
2·53 MAP2K5 Mitogen-activated protein kinase kinase 5
-1·55 -1·82 MAP3K4 Mitogen-activated protein kinase kinase kinase 4
-2·01 MAP4K3 Mitogen-activated protein kinase kinase kinase kinase 3
-2·14 MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5
2·50 -1·38 1·84 CALM1 Calmodulin 1 (phosphorylase kinase, delta)
1·78 -2·14 1·78 CAMK2G Calcium/calmodulin-dependent protein kinase II gamma
-1·96 PTPRB Protein tyrosine phosphatase, receptor type, B
3·01 PTPRO Protein tyrosine phosphatase, receptor type O
-2·19 PTPN21 Protein tyrosine phosphatase, non-receptor type 21
-1·51 2·08 2·07 DUSP22 Dual specificity phosphatase 22
1·22 -1·09 1·33 GNAI1 G protein-alpha inhibiting activity polypeptide 1
2·77 2·57 RGS1 Regulator of G-protein signalling 1
2·08 GNA15 G protein-alpha 15 (Gq class)
1·62 1·66 GNB1 G protein-beta polypeptide 1
-1·78 -2·20 RACGAP1 Rac GTPase activating protein 1
-2·50 -1·77 ARF6 ADP-ribosylation factor 6
1·75 -1·23 2·68 ARHGAP5 Rho GTPase activating protein 5
-2·38 HUMAUANTIG Nucleolar GTPase
2·35 1·57 GTPBP2 GTP binding protein 2
2·27 -1·67 DAPP1 Dual adaptor of phosphotyrosine and 3-phosphoinositides
10·85 KCND3 Shal-type potassium voltage-gated channel-3
2·11 2·35 KCNMA1 M-type potassium large conductance calcium-activated channel-1
-1·62 PDE4B cAMP phosphodiesterase 4B
-2·53 -2·04 PLD1 Phosphatidylcholine-specific phospholipase D1
2·58 1·79 PPAP2B Phosphatidic acid phosphatase type 2B
3·12 2·14 SGPP1 Sphingosine-1-phosphate phosphatase 1
4·72 PLCL1 Phospholipase C-like 1
2·46 1·05 DGKA Diacylglycerol kinase, alpha 80 kDa
-2·95 SPRY2 Sprouty homologue 2 (Drosophila)
-2·53 -4·06 WIF1 WNT inhibitory factor 1
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Table 1. Continued
LPS ES-62 ES-62/LPS Name Description
1·38 -1·01 1·48 BCAA RBP1-like protein
1·19 -1·03 1·20 SP110 SP110 nuclear body protein
1·12 -1·15 1·12 IFI16 Interferon-g-inducible protein 16
1·01 -1·06 1·11 NAP1L4 Nucleosome assembly protein 1-like 4
-2·08 RB1 Retinoblastoma 1
-2·60 -2·57 RARB Retinoic acid receptor, beta
2·66 1·60 NFYB Nuclear transcription factor Y, beta
1·92 2·06 CCND2 Cyclin D2
-2·03 CDK8 Cyclin-dependent kinase 8
-3·27 PPM1D Protein phosphatase 1D magnesium-dependent, delta isoform
1·12 -1·01 1·11 PDCD6 Programmed cell death 6
1·10 -1·21 -1·00 DAPK3 Death-associated protein kinase 3
Samples were derived with approval from the Glasgow Royal Infirmary Ethical Committee. Patients with RA fulfilled American College of
Rheumatology diagnostic criteria. Primary synovial membrane cultures (5 ¥ 106 cells) from RA and osteoarthritis (OA) patients were obtained by
digestion using collagenase as described previously [44] and were then exposed to media or ES-62 (2 mg/ml) for 2 h before being stimulated with media
or LPS (100 ng/ml) for a further 4 h. After extraction of mRNA, microarray analysis was carried out using the Affymetrix Human Genome Focus array
(HG Focus). The Affymetrix GeneChip version 5·0 software was used for image acquisition for the HG Focus chips. Data normalization, log
transformation, statistical analysis and pattern study were performed with GeneSpring version 7·0 software (Silicon Genetics, Redwood City, CA, USA)
setting the cut-off signal ratio at 1·5-fold change from the control OA samples, with the resultant data being expressed as fold change relative to the
control RA sample and differential gene expression identified by a two-way analysis of variance approach, as described previously [60].
Table 2. Genes up-regulated strongly by ES-62 in rheumatoid arthritis synovial membrane cultures.
Gene Biological process LPS ES-62 ES-62/LPS
Inhibitory leucocyte
immunoglobulin-like receptor,
subfamily B (with TM and ITIM
domains), member 2 (LILRB2)
Inhibitory receptors of which both membrane and soluble forms have
potent immunosuppressive activity which have potential for treating
transplant rejection, autoimmunity, asthma and cancer. LILRB suppress
development of osteoclasts responsible for bone resorption, transduction,
cellular defence response [62–64]
33·36 23·1
Oxidized low-density lipoprotein
(lectin-like) receptor 1 (OLR1)
Binds, internalizes and degrades oxidized low-density lipoprotein and
may play a role as a scavenger receptor associated with inflammatory
disorders such atherosclerosis and arthritis [66]
12·13 2·04 12·73
Complement receptor of the
immunoglobulin superfamily
(CRIg; Z39IG)
Expressed on tissue resident macrophages of synovium: clearance receptor
and inhibitor of alternative complement pathway [67,68]
11·71 12·38
Macrophage receptor with
collagenous structure (MARCO)
Scavenger receptor involved in clearance of pathogens and apoptotic cells;
reduced expression contributes to development of systemic lupus
erythematosus-like disease in mice [69–71]
4·20 33·82 23·75
CD163 antigen (CD163) Macrophage scavenger receptor: after shedding, the soluble form may
play an anti-inflammatory role, and may be diagnostic of macrophage
activation in inflammatory conditions. May be a marker of alternatively
activated macrophages [72,73]
10·56 13·55 13·64
Signalling lymphocytic activation
molecule (SLAMF1)
Self-ligand involved in inhibiting CD40-mediated proinflammatory
responses in DCs and their ability to prime Th1 responses and also
IL-4/IL-10-secreting NKT2 differentiation in NOD mice [74,75]
7·94 9 8·51
DAP12 (TYRO protein tyrosine
kinase binding protein)
ITAM-containing adaptor: transduces TREM-1 and 2 signals to activate
myeloid cells. Although TREM signalling can synergize with that of LPS,
TREM-1 activation also attenuates the induction of some LPS target
genes, including those that encode IL-12 cytokine family subunits. This is
because TREM-2 via DAP12 negatively regulates TLR and FcR signals. In
addition, acts, via APC, to control the level of anti-microbial type 1 T cell
activation and immunopathology [76,77]
4·59 5·78 3·92
Major histocompatibility complex,
class II (HLA-DRA)
Antigen presentation 10·93 6·32 8·11
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immune system cells, including those dependent upon
phosphoinositide-3 (PI-3) kinase, sphingosine kinase/
phospholipase D (SphK/PLD), mitogen-activated protein
(MAP) kinases and nuclear factor kappa B (NF-kB)
[42,48,49], suggesting that targeting of such signals may
ameliorate inflammatory disease. Inhibitors of many of these
pathways are currently undergoing clinical trials in a variety
of inflammatory diseases, including asthma and arthritis,
but due to their widespread expression, multiple isoforms
and essential roles there are generally debilitating associated
side effects, although the recent development of isoform-
specific inhibitors may go some way to addressing these
problems [51,95,96]. Another approach is to target particu-
lar isoforms specifically by in vivo siRNA therapy [97], and
in this way we have recently used siRNA specific for SphK1
to ameliorate pathology successfully in mouse models of
arthritis, airway hyper-reactivity and mast cell-dependent
anaphylaxis [98–100]. Alternatively, as many of these signal-
ling elements exert their effects via protein–protein (or
protein–DNA, protein–lipid) interactions using well-defined
modular (e.g. SH2, SH3, PH) domains rather than/in addi-
tion to their intrinsic enzyme activities, cell-permeable
peptides that disrupt these interactions have been used suc-
cessfully to block such signals both in vitro and in vivo
[39,101,102]. Thus, building upon the data generated by
microarray (Tables 1 and 2) and consequent proteomics
studies to identify the precise ‘blueprint’ of key signalling
molecules targeted by ES-62 in a particular inflammatory
Table 2. Continued
Gene Biological process LPS ES-62 ES-62/LPS
GPR109A (nicotinic acid receptor:
PUMA-G, HM74)
Up-regulated by IFN-g in macrophages 6·87 8·57 7·41
Chemokine (C-C motif) ligand 4
(CCL4; MIP-1b)
Proinflammatory chemokine involved in the host response to infection
and inflammatory disorders including asthma and arthritis [78]
4·86 9·58 10·34
Chemokine (C-X-C motif) ligand 13 Contributes to inflammation and ectopic G C formation in synovial
tissue and is a potential biomarker for rheumatoid arthritis. Also
associated with asthma-like inflammation [79,80].
6·15 6·15 6·19
Neuromedin U (NMU) Neuropeptide that promotes Th2 cell, mast cell, eosinophil and monocyte
inflammation in asthma, sepsis [81–84]
29·86
Complement 1qa (C1QA) Complement activation, classical pathway 19·43 20·11 16·22
Fucosyltransferase 4 (alpha (1,3)
fucosyltransferase, myeloid-specific)
(FUT4)
Cell adhesion based on E-selectin ligand activity, particularly eosinophils
[85]
12·04 8·63
Epoxygenase [cytochrome P450,
family 2, subfamily J, polypeptide 2
(CYP2J2)]
Produces the anti-inflammatory arachidonic acid metabolites,
epoxyeicosatrienoic acids (EETs), which regulate vascular tone, cellular
proliferation, migration, inflammation and cardiac function. While
down-regulation of epoxygenases leads to renal damage, overexpression of
CYP2J2 decreases cytokine-induced endothelial cell adhesion molecule
expression. Moreover EETs prevent leucocyte adhesion to the vascular
wall by inhibition of IkB kinase and NF-kB [86,87]
13·09
Aquaporin 3 (AQP3) Water/glycerol transport channels implicated in hydration and repair
of epithelial/endothelial barriers; down-regulated by TNF in skin.
Up-regulated in IL-13-associated asthma and altered localization may
be a contributing factor to diarrhoea during bacterial infection [88]
4·99 7·52 6·11
Potassium voltage-gated channel,
Shal-related subfamily, member 3
(KCND3)
Potassium ion transport 10·85
Haemopoietic cell kinase (HCK) Regulation of phagocytosis, adhesion and migration and hence
inflammation [89]
5·1 5·17 4·03
UBP43 (ubiquitin-specific protease
18)
De-ubiquitination enzyme (DUB) that deconjugates ISG15 which is an
IFN-inducible ubiquitin-like protein whose expression and conjugation to
target proteins are induced dramatically upon viral or bacterial infection.
UBP43-deficient mice are hypersensitive to LPS-induced lethality
6·59 5·78 7·26
Myeloid cell nuclear differentation
antigen (MNDA)
Regulation of transcription and cell death. Highly expressed in arthritis
patients and member of family implicated in SLE susceptibility [90,91]
95·67 247·28 183·55
APC: antigen-presenting cells; IL: interleukin; LPS: lipopolysaccharide; NOD: non-obese diabetic; NF-kB: nuclear factor kappa B; Th1: T helper type
1; TNF: tumour necrosis factor; TREM: triggering receptor expressed on myeloid cells; TLR: Toll-like receptor.
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cell or target organ could allow the development of such
target-based therapeutics, rather than PC-based SMDs,
to mimic ES-62-mediated suppression of disease-specific
inflammatory signalling pathways.
For example, peptides targeting interactions of inhibitor of
kB (IkB) and NF-kB essential modulator (NEMO) prevent
activation of NF-kB and consequent release of inflammatory
mediators without affecting basal or protective NF-kB activ-
ity [101,102]. Indeed, employing a variety of cell-permeable
protein transduction domain (PTD) peptides to provide sys-
temic delivery of one such peptide (NBD) demonstrated it to
be therapeutic in mouse models of arthritis, inflammatory
bowel disease, diabetes and muscular dystrophy [101,102].
Moreover, as many signalling elements often have more than
one adaptor domain, it should be possible to select peptides
that target particular individual interactions [103,104],
allowing subtle modulation of cellular responses. This
approach has been used successfully for immune cell surface
receptors (e.g. the chemokine receptors, CCR2, CCR3,
CCCR5 and CXCR4 [104,105]) and intracellular signalling
molecules involved in cytokine signalling, such as signal
transducer and activator of transcription 3 (STAT3) [103],
and could be applied to mimicking of ES-62-mediated dis-
ruption of TLR signalling that requires TLR dimerization
and/or interaction with TIR-containing adaptors such as
myeloid differentiation primary response gene 88 (MyD88)
for initiating proinflammatory cytokine secretion.
Perhaps of particular relevance to ES-62, given its selective
action towards protein kinase C isoforms [48,49], are
the peptide inhibitors specific for enzyme-substrate/
pseudosubstrate interaction sites [106] which might
mimic ES-62 by blocking, for example, isoform-
specific PKCs. Alternatively, peptidomimetic compounds
(e.g. phosphonate-based pTyr mimetics) that disrupt SH2-
phosphotyrosine interactions [106,107] might reproduce
ES-62-mediated targeting of certain Src-related protein
tyrosine kinases and consequent uncoupling of the B cell
antigen receptor (BCR) from the RasMAPkinase pathway
driven by recruitment of SHP-1 phosphatase [48,49]. Impor-
tantly, the structural modifications (e.g. mono- or difluoro-
derivatives) of the phosphonates used to promote stability
and bioavailability [106,107] have also allowed differential
targeting of distinct SH2 domains. For example, while a
difluoro-derivative of a phosphonate peptide displays
equivalent affinity to the PI-3K SH2 domain, it was
more potent towards Src SH2 domains and less effective
against Grb2 SH2 domains than the parent pTyr-peptide
[106,108,109]. Other key targets of ES-62 action, the
extracellular-regulated kinase (ERK), p38 and c-Jun
N-terminal kinase (JNK) MAP kinases, can be regulated via
interaction with scaffold proteins containing kinase interac-
tion motifs (KIM) such as kinase interacting protein (KIP)
and JNK-interacting protein (JIP) [107]. Inhibitory peptides
that resemble the KIM of JIP have been developed which
when fused to the TAT cell-permeable PTD sequence have
been found to block Jnk activity [110]. As ES-62 selectively
targets these kinases to differentially modulate IL-12 and
TNF-a secretion from macrophages [48,49,111], combina-
tion therapy using such peptides may be able to modulate
specifically both the precise phenotype and the extent of the
inflammatory response. Indeed, given the therapeutic poten-
tial of ES-62 in a variety of inflammatory pathologies, the
recent development of a peptide phage display library screen
for tissue specific delivery that has produced efficient PTDs
that transport proteins selectively into tumours, airway epi-
thelia, synovial fibroblasts and cardiac tissue render this
approach clinically useful in vivo [112]. Moreover, by testing
whether such pharmacological modulation of helminth
targets results in a similar ‘blueprint’ to the anti-
inflammatory action of parasite-derived immunomodula-
tors in clinically relevant tissues, this parasite-based
approach may identify safe, novel therapeutic targets collec-
tively, in that they have been validated over millennia by the
host–parasite relationship.
Disclosure
MM Harnett, AJ Melendez and W Harnett report no con-
flicts of interest.
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